# African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola

> **NCT03031912** · PHASE2 · COMPLETED · sponsor: **Canadian Immunization Research Network** · enrollment: 251 (actual)

## Conditions studied

- Ebola

## Interventions

- **BIOLOGICAL:** V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT03031912
- **Lead sponsor:** Canadian Immunization Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2023-03-03
- **Final completion:** 2023-03-03
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03031912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03031912, "African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03031912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*